Comment on

• Overestimating the Benefit of Cancer Drugs.

  Prasad V. Prasad V. JAMA Oncol. 2017 Dec 1;3(12):1737-1738. doi: 10.1001/jamaoncol.2017.0107. JAMA Oncol. 2017. PMID: 28715568 No abstract available.
• Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.

  Gyawali B, Prasad V. Gyawali B, et al. JAMA Oncol. 2018 Jan 1;4(1):17-18. doi: 10.1001/jamaoncol.2017.1944. JAMA Oncol. 2018. PMID: 28750129 No abstract available.
• Is "Do Everything!" Always Appropriate?-Reply.

  Beer TM, Prasad V. Beer TM, et al. JAMA Oncol. 2017 Nov 1;3(11):1588. doi: 10.1001/jamaoncol.2017.2349. JAMA Oncol. 2017. PMID: 28817761 No abstract available.
• Overall Survival vs Disease-Specific Survival-Reply.

  Mailankody S, Prasad V. Mailankody S, et al. JAMA Oncol. 2018 Apr 1;4(4):586-587. doi: 10.1001/jamaoncol.2017.3865. JAMA Oncol. 2018. PMID: 29167883 No abstract available.
• Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.

  Prasad V, Kaestner V, Mailankody S. Prasad V, et al. JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182. JAMA Oncol. 2018. PMID: 29285544 No abstract available.
• Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.

  Hernandez I, Prasad V, Gellad WF. Hernandez I, et al. JAMA Oncol. 2018 Jul 1;4(7):994-996. doi: 10.1001/jamaoncol.2018.0977. JAMA Oncol. 2018. PMID: 29710129 Free PMC article.
• Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

  Marquart J, Chen EY, Prasad V. Marquart J, et al. JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660. JAMA Oncol. 2018. PMID: 29710180 Free PMC article.
• Missing Conflict of Interest Disclosure.

  [No authors listed] [No authors listed] JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.4091. JAMA Oncol. 2018. PMID: 30128482 Free PMC article. No abstract available.